Claritas Pharmaceuticals Inc V.CLAS.H

material change

[monkey245]

Kalytera Therapeutics, Inc. MATERIAL CHANGE REPORT Item 1: Name and Address of Company Kalytera Therapeutics, Inc. (the “Company” or “Kalytera”) 4040 Civic Center Drive Suite 200 San Rafael, California, USA, 94903 Item 2: Date of Material Change January 22, 2021 Item 3: News Release A news release was issued and disseminated through the facilities of Baystreet and Stockwatch on January 22, 2021, and filed on SEDAR (www.sedar.com). A copy of the news release is attached as Schedule “A” hereto. Item 4: Summary of Material Change On January 22, 2021 the Company’s previously announced FFCTO was fully revoked by the British Columbia Securities Commission and the Ontario Securities Commission. The Company is following up with the TSXV to remove its suspension and resume the trading of the Company’s common shares, which resumption when effected will be confirmed in a follow up press release. The Company confirms that its business has not changed, the Company remains active, and there are no changes to its current business plans. Readers are urged to review the attached news release at Schedule "A" to this report for complete details on the above mentioned matters. Item 5: Full Description of Material Change See attached news release at Schedule "A" to this report. Item 6: Reliance on Subsection 7.1(2) of National Instrument 51-102 Not applicable. Item 7: Omitted Information Not applicable. Item 8: Executive Officer The following executi